Vaccine Adjuvants Derivatized from Momordica Saponins I and II

J Med Chem. 2019 Nov 14;62(21):9976-9982. doi: 10.1021/acs.jmedchem.9b01511. Epub 2019 Oct 28.

Abstract

We have derivatized Momordica saponins (MS) I and II through their coupling at C3 glucuronic acid site with dodecylamine. The derivatives show significantly different immunostimulant activity profiles from their respective natural parent saponins. In particular, adjuvant VSA-1 (5), the derivative of MS I, potentiates a significantly higher IgG2a responose than the corresponding natural product. Its IgG1 and IgG2a production is similar to that of GPI-0100, indicating a potential mixed and antigen-specific Th1/Th2 immune response, which is different from the Th2 immunity induced by the natural saponin MS I. In addition, toxicity evaluations show that adjuvant VSA-1 (5) is much less toxic than the widely used natural saponin mixture Quil A. These results prove that derivatizing Momordica saponins can be a viable way for easy access to structurally defined saponin immunostimulants with favorable adjvuant activity and low toxicity.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adjuvants, Immunologic / chemistry*
  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Immunity, Humoral / drug effects
  • Immunization
  • Mice
  • Momordica / chemistry*
  • Saponins / chemistry*

Substances

  • Adjuvants, Immunologic
  • Saponins